Supplementary Table 2 from Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

XLSX file - 213K, Table S2. Summary of in vivo activity of BKM120, BYL719, RAD001 and BEZ235 in breast cancer tumor models. T/C: Ratio of mean tumor volume of treated (T) to control (C) at final day of treatment. Final day was determined as the final day of treatment for the vehicle control arm for each study in Figure 5. Comparisons between groups were all made by Repeated Measures ANOVA (RMANOVA) followed by Dunnett test for multiple comparisons. BW: body weight; TR: treatment related; NTR: non-treatment related.XLSX文件 - 213K，附表S2。本文件汇总了BKM120、BYL719、RAD001及BEZ235在乳腺癌肿瘤模型中的体内活性数据。T/C：治疗结束当日处理组（Treated, T）平均肿瘤体积与对照组（Control, C）平均肿瘤体积的比值。本研究的治疗结束日以图5中各实验的溶剂对照组的治疗终止日为准。组间比较均采用重复测量方差分析（Repeated Measures ANOVA, RMANOVA），随后采用Dunnett检验进行多重比较。BW：体重（Body Weight）；TR：治疗相关（Treatment Related）；NTR：非治疗相关（Non-treatment Related）。